An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C patients with vitaminD plus peginterferon alpha-2a /ribavirin.versus alfacalcidol plus peginterferon alpha-2a /ribavirin. - Vitamin D or Alfacalcidol with peginterferon alfa-2a plus ribavirin for treatment of chronic hepatitis C patients

Saitama Medical University0 sites40 target enrollmentSeptember 17, 2010

Overview

Phase: 未知
Intervention: Not specified
Conditions: Chronic hepatitis C patients with genotype 1 and high viral load (&gt
Sponsor: Saitama Medical University
Enrollment: 40
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

September 17, 2010

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•The following patients were excluded 1\)Women of childbearing potential and pregnancy, lactating woman 2\) allergic to ribavirin or nucleoside analogues 3\)an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia) 4\)hemoglobinopathy(thalassemia, sickle cell disease) 5\) severe renal disease, Ccr \<50ml/min 6\) severe depression or psychosomatic disorders 7\)severe liver disease 8\) autoimmune hepatitis or HBV 9\) drug allergy against interferon 10\) Allergic to vaccine or biological preparations 11\) Concomitant herbal medication of Sho\-saikoto 12\) history of interstitial pneumonia 13\)Other conditions considered inappropriate by attending physician